title: Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis.
abstract: This 28-d, open-label, multicenter, single-arm clinical study was designed to evaluate perceptions of olopatadine 0.2% in patients with active ocular allergic signs and symptoms. The study enrolled 330 patients, 5 to 94 y of age, who had previously used olopatadine 0.1% for active allergic conjunctivitis. Most patients were white (n=230; 70.1%) and female (n=239; 72.9%). Of all enrolled patients, 328 were evaluable for analysis. Throughout the study, patients instilled 1 drop of olopatadine 0.2% into each eye once daily; adverse events were documented and ocular evaluations were conducted to ensure patient safety. Direct evaluations of efficacy were not performed. On days 1 and 7, patients completed the Rhinoconjunctivitis Quality of Life Questionnaire, recorded their perceptions of olopatadine 0.1% (day 1) or 0.2% (day 7), and had their ocular allergies assessed globally. On each of the first 6 d of treatment, patients also completed a telephone-based perception questionnaire. On day 28, patients returned to the study center, reported their treatment perceptions, had their ocular allergies assessed, and exited the trial. Overall, patients had a positive perception of olopatadine 0.2%. Patients were more satisfied with olopatadine 0.2% than they remembered being with olopatadine 0.1% (289 vs 257 patients; 87.6% vs 77.8%; P<.05). The majority of the 48 patients who wore contact lenses (n=42; 88%) believed that they could wear their contacts as desired. Significant improvement was noted in all categories of the Rhinoconjunctivitis Quality of Life Questionnaire (P<.0001). No unexpected safety findings were reported. Patients perceived olopatadine 0.2% to be effective and well tolerated.
authors.affiliation: Virginia Eye Consultants, Norfolk, Virginia 23507, USA. sscoper@vec2020.com
authors.forename: Stephen V
authors.initials: SV
authors.lastname: Scoper
authors.forename: Gregg J
authors.initials: GJ
authors.lastname: Berdy
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Lichtenstein
authors.forename: Jay M
authors.initials: JM
authors.lastname: Rubin
authors.forename: Marc
authors.initials: M
authors.lastname: Bloomenstein
authors.forename: Robert E
authors.initials: RE
authors.lastname: Prouty
authors.forename: Cullen T
authors.initials: CT
authors.lastname: Vogelson
authors.forename: Michael R
authors.initials: MR
authors.lastname: Edwards
authors.forename: Curtis
authors.initials: C
authors.lastname: Waycaster
authors.forename: Terri
authors.initials: T
authors.lastname: Pasquine
authors.forename: Robert D
authors.initials: RD
authors.lastname: Gross
authors.forename: Stella M
authors.initials: SM
authors.lastname: Robertson
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000523:psychology; D003990:Dibenzoxepins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069605:Olopatadine Hydrochloride; D017060:Patient Satisfaction; D010465:Perception; D011788:Quality of Life
chemical_list: D018926:Anti-Allergic Agents; D003990:Dibenzoxepins; D000069605:Olopatadine Hydrochloride